NP339 is being developed as a treatment for IFD as Novamycin®, currently in an IND enabling toxicology programme ahead of entering the clinical development stage. As the first peptide ever developed for systemic administration in fungal infections, the next stages in this exciting drug candidates' pathway could represent significant breakthroughs in the field of IFD therapy and antimicrobial peptide drug development.

In an ageing population and one more frequently subjected to treatments which suppress the immune system, fungal infection represents an increasing burden on global health-care systems. Total costs incurred in treating deep seated fungal infections can run to tens of thousands of pounds per patient. Currently available treatments for bloodstream and deep-tissue fungal infections have survival rates as low as 20% and are associated with a range of serious complications and side-effects. Drug resistance is a very significant issue which impacts markedly on treatment options for patients. There is an obvious and immediate need to provide novel therapeutic solutions to this significant clinical problem; representing a global market forecast worth in excess of $5.7 billion for systemic mycoses/IFD alone. As a potent antifungal peptide that rapidly kills target pathogens in such a way as to minimise, if not negate the chances of drug resistance in target fungal organisms, NP339 represents one potential solution.